Evidence map›Paper›PMID 26301928›Full record

ArticleMonoclonal antibodies in immunodiagnosis and immunotherapy2015

A Novel Monoclonal Antibody Against Human DAB2IP.

He Xu, Dapeng Wei, Jianxin Xue, Lijuan Hu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Monoclonal antibodies in immunodiagnosis and immunotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

He Xu1 Department of Immunology, West China School of Preclinical and Forensic Medicine, Sichuan University , Chengdu, China .
Dapeng Wei1 Department of Immunology, West China School of Preclinical and Forensic Medicine, Sichuan University , Chengdu, China .
Jianxin Xue2 Department of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University , Chengdu, China .
Lijuan Hu1 Department of Immunology, West China School of Preclinical and Forensic Medicine, Sichuan University , Chengdu, China .
Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DAB2 interactive protein (DAB2IP), also known as ASK1-interacting protein-1 (AIP1), a novel member of the RasGTPase-activating protein family, plays a key role in tumor suppression during cancer progression and is highly expressed in vascular smooth muscle cells (VSMCs) and endothelial cells (ECs). To further explore its function as a cancer suppressor, in this study, we immunized BALB/c mice with synthesized human DAB2IP polypeptide and obtained a novel monoclonal antibody (MAb) against human DAB2IP. A stable strain of hybridoma was screened and successfully established by the hybridoma technique. The immunohistochemistry, immunocytochemistry, and Western blot analysis revealed that the MAb was directed against human DAB2IP with high specificity. Therefore, this MAb may be a useful tool and facilitate studies on tumorigenesis associated with DAB2IP.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsAntibodies, MonoclonalApoptosis Regulatory ProteinsCarcinogenesisFemaleHumansMiceMice, Inbred BALB CTumor Suppressor ProteinsAdaptor Proteins, Signal TransducingAntibodies, MonoclonalApoptosis Regulatory ProteinsDAB2 protein, humanTumor Suppressor Proteins

Identifiers

PMID26301928
PMCPMC4554931
OpenAlexW1151931741

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.